Crispr Therapeutics Valuation
| CRSP Stock | USD 46.29 0.97 2.05% |
At this time, the firm appears to be overvalued. Crispr Therapeutics shows a prevailing Real Value of $40.74 per share. The current price of the firm is $46.29. Our model approximates the value of Crispr Therapeutics from analyzing the firm fundamentals such as Return On Equity of -0.13, profit margin of (1.18) %, and Current Valuation of 2.33 B as well as examining its technical indicators and probability of bankruptcy. Key fundamental drivers impacting Crispr Therapeutics' valuation include:
Price Book 2.0796 | Enterprise Value 2.3 B | Enterprise Value Ebitda 14.1584 | Price Sales 19.8877 | Forward PE 23.3645 |
Overvalued
Today
Please note that Crispr Therapeutics' price fluctuation is very steady at this time. Calculation of the real value of Crispr Therapeutics is based on 3 months time horizon. Increasing Crispr Therapeutics' time horizon generally increases the accuracy of value calculation and significantly improves the predictive power of the methodology used.
Crispr Therapeutics' intrinsic value may or may not be the same as its current market price of 46.29, in which case there is an opportunity to profit from the mispricing, assuming the market price will eventually merge with its intrinsic value. | Historical | Market 46.29 | Real 40.74 | Target 88.13 | Hype 47.26 | Naive 43.42 |
The intrinsic value of Crispr Therapeutics' stock can be calculated using various methods such as discounted cash flow analysis, price-to-earnings ratio, or price-to-book ratio. That value may differ from its current market price, which is determined by supply and demand factors such as investor sentiment, market trends, news, and other external factors that may influence Crispr Therapeutics' stock price. It is important to note that the real value of any stock may change over time based on changes in the company's performance.
Estimating the potential upside or downside of Crispr Therapeutics AG helps investors to forecast how Crispr stock's addition to their portfolios will impact the overall performance. We also use other valuation drivers to help us estimate the true value of Crispr Therapeutics more accurately as focusing exclusively on Crispr Therapeutics' fundamentals will not take into account other important factors: Traditionally, analysts and sophisticated investors use multiple methods for valuing a cash-flow-generating entity or its stock. For example, some money managers use Crispr Therapeutics' intrinsic value based on its ongoing forecasts of Crispr Therapeutics' financial statements. In contrast, other private, professional wealth advisors use a multiplier approach by looking to relative value analysis against Crispr Therapeutics' closest peers.
Crispr Therapeutics Cash |
|
Crispr Valuation Trend
Crispr Therapeutics' real value is important for investors to make better decisions and a more accurate overall view of Crispr Therapeutics' financial worth over time. Using both Crispr Therapeutics' enterprise value as well as its market capitalization is the best way to gauge the value of the company and is usually enough for investors to make market timing conclusions.
Crispr Therapeutics Total Value Analysis
Crispr Therapeutics AG is currently projected to have valuation of 2.33 B with market capitalization of 4.03 B, debt of 238.63 M, and cash on hands of 2.07 B. Please note that valuation may be misleading and is a subject to auditing or accounting errors. We encourage investors to vigilantly validate all of the Crispr Therapeutics fundamentals before making equity appraisal based on enterprise value of the company| Takeover Price | Market Cap | Debt Obligations | Cash |
2.33 B | 4.03 B | 238.63 M | 2.07 B |
Crispr Therapeutics Investor Information
About 72.0% of the company shares are held by institutions such as insurance companies. The book value of Crispr Therapeutics was currently reported as 22.73. The company recorded a loss per share of 2.79. Crispr Therapeutics had not issued any dividends in recent years. The entity had 333333:100 split on the 19th of July 2016. Based on the key indicators related to Crispr Therapeutics' liquidity, profitability, solvency, and operating efficiency, Crispr Therapeutics AG is not in a good financial situation at this time. It has a very high odds of going through financial crisis in December.Crispr Therapeutics Asset Utilization
The asset utilization indicator refers to the revenue earned for every dollar of assets a company currently reports. Crispr Therapeutics has an asset utilization ratio of 16.65 percent. This connotes that the Company is making $0.17 for each dollar of assets. An increasing asset utilization means that Crispr Therapeutics AG is more efficient with each dollar of assets it utilizes for everyday operations.Crispr Therapeutics Ownership Allocation
Crispr Therapeutics holds a total of 85.35 Million outstanding shares. The majority of Crispr Therapeutics AG outstanding shares are owned by other corporate entities. These outside corporations are usually referred to as non-private investors looking to acquire positions in Crispr Therapeutics to benefit from reduced commissions. Consequently, institutional investors are subject to a different set of regulations than regular investors in Crispr Therapeutics. Please pay attention to any change in the institutional holdings of Crispr Therapeutics AG as this could imply that something significant has changed or is about to change at the company. On October 5, 2021, Representative Thomas Suozzi of US Congress acquired $50k to $100k worth of Crispr Therapeutics's common stock.Crispr Therapeutics Profitability Analysis
The company reported the previous year's revenue of 371.21 M. Net Loss for the year was (153.61 M) with loss before overhead, payroll, taxes, and interest of (570.7 M).About Crispr Therapeutics Valuation
The stock valuation mechanism determines Crispr Therapeutics' current worth on a daily basis. In general, an absolute valuation approach attempts to find the value of Crispr Therapeutics based exclusively on its fundamental and basic technical indicators. As compared to an absolute model, our relative valuation model uses a comparative analysis of Crispr Therapeutics. We calculate exposure to Crispr Therapeutics's market risk, different technical and fundamental indicators, and relevant financial multiples and ratios and then compare them to those of Crispr Therapeutics's related companies.| Last Reported | Projected for Next Year | ||
| Gross Profit | 241 M | 122.4 M | |
| Pretax Profit Margin | (0.41) | (0.43) | |
| Operating Profit Margin | (0.60) | (0.63) | |
| Net Loss | (0.41) | (0.43) | |
| Gross Profit Margin | 0.65 | 0.68 |
Crispr Therapeutics Growth Indicators
Investing in growth stocks can be very risky. If the company such as Crispr Therapeutics does not do well, investors take a loss on the stock when it is time to sell. Also, because growth stocks typically do not pay dividends, the only opportunity an investor has to make money on their investment is when they eventually sell their shares.
| Common Stock Shares Outstanding | 79.2 M | |
| Forward Price Earnings | 23.3645 |
Crispr Therapeutics Current Valuation Indicators
Crispr Therapeutics' valuation analysis is a process of estimating the intrinsic value of all assets and outstanding equities. There are different methodologies and models we use to develop the final Crispr Therapeutics' valuation. The techniques such as discounted cash flow and fundamental indicators such as book value per share or market capitalization are well known and widely used across most financial advisers and money managers.
Valuations are an essential part of business, for companies themselves, but also for investors. For companies, such as Crispr Therapeutics, valuations can help measure their progress and success and can help them track their performance in the market compared to others. In addition, investors can use Crispr Therapeutics' valuations to help determine the worth of potential investments. They can do this by using data and information made public by a company. Regardless of who the valuation is for, it essentially describes Crispr Therapeutics' worth.Additional Tools for Crispr Stock Analysis
When running Crispr Therapeutics' price analysis, check to measure Crispr Therapeutics' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Crispr Therapeutics is operating at the current time. Most of Crispr Therapeutics' value examination focuses on studying past and present price action to predict the probability of Crispr Therapeutics' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Crispr Therapeutics' price. Additionally, you may evaluate how the addition of Crispr Therapeutics to your portfolios can decrease your overall portfolio volatility.